Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 6/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 2/20 | 0.40 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871309 | 0.89 | TBK1 (0.38) | TBK1EGFRJAK3SIRT5PDPK1 | |
| SCHEMBL3865006 | 0.87 | TBK1 (0.49) | TBK1EGFRSIRT5PDPK1CDK2 | |
| SCHEMBL6543862 | 0.87 | EGFR (0.40) | TBK1EGFRJAK3SIRT5PDPK1 | |
| SCHEMBL3869593 | 0.87 | TBK1 (0.51) | TBK1EGFRJAK3SIRT5PDPK1 | |
| SCHEMBL6452492 | 0.84 | TBK1 (0.45) | TBK1SIRT5PDPK1CDK2STK17A | |
| SCHEMBL13897407 | 0.79 | TBK1 (0.46) | TBK1EGFRJAK3SIRT5PDPK1 | |
| SCHEMBL13897635 | 0.79 | SIRT5 (0.48) | TBK1EGFRSIRT5ITK | |
| SCHEMBL27635330 | 0.76 | EGFR (0.48) | TBK1EGFRJAK3PDPK1CDK2 | |
| SCHEMBL3871516 | 0.74 | TBK1 (0.41) | TBK1EGFRJAK3SIRT5PDPK1 | |
| SCHEMBL3966147 | 0.73 | EGFR (0.45) | TBK1EGFRJAK3SIRT5CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | TBK1 452/4885EGFR 747/4885JAK3 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.